Federated Hermes
TRML

Federated Hermes’s Tourmaline Bio TRML Stock Holding History

Federated Hermes’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-121,245
Closed -$1.84M – 2188
2025
Q1 		$1.84M Buy
121,245
+120,322
+13,036% +$1.93M ﹤0.01% 955
2024
Q4 		$18.7K Buy
+923
New +$23.2K ﹤0.01% 1775
2024
Q2 		– Sell
-357
Closed -$8.18K – 2136
2024
Q1 		$8.18K Buy
357
+213
+148% +$7.51K ﹤0.01% 1797
2023
Q4 		$3.77K Sell
144
-91
-39% -$1.82K ﹤0.01% 1884
2023
Q3 		$6.6K Sell
235
-33
-12% -$966 ﹤0.01% 1863
2023
Q2 		$8.16K Buy
268
+7
+3% +$179 ﹤0.01% 1865
2023
Q1 		$4.91K Buy
261
+93
+55% +$1.53K ﹤0.01% 1937
2022
Q4 		$1.71K Buy
+168
New +$2.7K ﹤0.01% 2019

Other funds holding TRML

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

Federated Hermes's TRML Position: Q2 2025 in Review

Federated Hermes sold out of Tourmaline Bio (TRML) in Q2 2025, closing a stake of 121,245 shares — an estimated $1.84M sold.

Federated Hermes first reported a position in TRML in Q4 2022 and held it in 8 quarters. The position peaked at $1.84M in Q1 2025. 108 funds tracked by Wall St. Rank hold TRML as of Q2 2025.

  • Federated Hermes reported no remaining Tourmaline Bio position as of Q2 2025 after selling out during the quarter.
  • Federated Hermes sold 121,245 Tourmaline Bio shares in Q2 2025, an estimated $1.84M.
  • Federated Hermes first reported a position in Tourmaline Bio in Q4 2022 and held it in 8 quarters.
  • Federated Hermes's Tourmaline Bio position peaked at $1.84M in Q1 2025.
  • 108 funds tracked by Wall St. Rank held Tourmaline Bio as of Q2 2025.

Based on Federated Hermes's 13F filing for Q2 2025, filed 13 Aug 2025.